GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Institutional Ownership

PRFX (PainReform) Institutional Ownership : 4.97% (As of Apr. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is PainReform Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PainReform's institutional ownership is 4.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PainReform's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PainReform's Float Percentage Of Total Shares Outstanding is 45.53%.


PainReform Institutional Ownership Historical Data

The historical data trend for PainReform's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Institutional Ownership Chart

PainReform Historical Data

The historical data trend for PainReform can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30
Institutional Ownership 0.11 0.11 0.11 0.10 0.06 0.06 0.06 0.06 0.03 0.01

PainReform Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PainReform Business Description

Traded in Other Exchanges
N/A
Address
65 Yigal Alon Street, Tel Aviv, ISR, 6744316
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.